MannKind Corp

mannkindcorp.com

The filing excerpts provided do not contain sufficient substantive business information about MannKind Corp (NASDAQ: MNKD) to construct a SEC-grounded canonical description. The excerpts consist entirely of boilerplate SEC cover page language and do not disclose the company's business activities, revenue model, products, customers, competitors, geographic footprint, or financial figures. No supported description can be written from the available source material.

Peers: Arcellx Inc TG Therapeutics Inc IGM Biosciences, Inc. Mirum Pharmaceuticals Inc Northwest Biotherapeutics Inc Viridian Therapeutics Inc Replimune Group Inc Sangamo Therapeutics Inc Seres Therapeutics Inc

Source: SEC 10-K, filed 2026-02-26

Dive deeper

Financial Snapshot

Revenue

TTM

$360.8M

Gross Margin

TTM

88.89%

Net Income

TTM

-$23.08M

Current Assets

2026 Q1

$251.2M

Current Liabilities

2026 Q1

$134.6M

Current Ratio

2026 Q1

186.65%

Total Assets

2026 Q1

$744.4M

Total Liabilities

2026 Q1

$803.6M

Book Value

2026 Q1

-59.20M

Cash

2026 Q1

$52.83M

P/E

Last 4 Quarters

N/A

Free Cash Flow

TTM

$13.15M

Stock Price

Market Cap: $1.2636 Billion